Open-Angle Glaucoma – Pipeline Review, H1 2016

$2,000

The report provides comprehensive information on the therapeutics under development for Open-Angle Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research…….

Total Pages: 121

Global Markets Direct’s, ‘Open-Angle Glaucoma - Pipeline Review, H1 2016’, provides an overview of the Open-Angle Glaucoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Open-Angle Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Open-Angle Glaucoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma
- The report reviews pipeline therapeutics for Open-Angle Glaucoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Open-Angle Glaucoma therapeutics and enlists all their major and minor projects
- The report assesses Open-Angle Glaucoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Open-Angle Glaucoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Open-Angle Glaucoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Open-Angle Glaucoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Open-Angle Glaucoma Overview 10
Therapeutics Development 11
Pipeline Products for Open-Angle Glaucoma - Overview 11
Pipeline Products for Open-Angle Glaucoma - Comparative Analysis 12
Open-Angle Glaucoma - Therapeutics under Development by Companies 13
Open-Angle Glaucoma - Therapeutics under Investigation by Universities/Institutes 16
Open-Angle Glaucoma - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Open-Angle Glaucoma - Products under Development by Companies 21
Open-Angle Glaucoma - Products under Investigation by Universities/Institutes 23
Open-Angle Glaucoma - Companies Involved in Therapeutics Development 24
Aerie Pharmaceuticals, Inc. 24
Allergan Plc 25
Amakem NV 26
Asahi Kasei Pharma Corp. 27
Bausch & Lomb Incorporated 28
F. Hoffmann-La Roche Ltd. 29
Inotek Pharmaceuticals Corporation 30
Kowa Company, Ltd. 31
Lee's Pharmaceutical Holdings Limited 32
Ocular Therapeutix, Inc. 33
Ono Pharmaceutical Co., Ltd. 34
Otsuka Holdings Co., Ltd. 35
Oxford BioMedica Plc 36
Sanofi 37
Santen Pharmaceutical Co., Ltd. 38
Senju Pharmaceutical Co., Ltd. 39
Sun Pharma Advanced Research Company Ltd. 40
Sylentis S.A.U. 41
ViSci Ltd. 42
vTv Therapeutics LLC 43
Open-Angle Glaucoma - Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Combination Products 45
Assessment by Target 46
Assessment by Mechanism of Action 49
Assessment by Route of Administration 51
Assessment by Molecule Type 53
Drug Profiles 55
(carteolol hydrochloride + latanoprost) - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
(dorzolamide hydrochloride + latanoprost) - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
(latanoprost + trabodenoson) - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
(tafluprost + timolol maleate) - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
AMA-0076 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Antisense Oligonucleotides to Inhibit P16INK4a for Primary Open-Angle Glaucoma (POAG) - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ATS-8535 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
bamosiran - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
bimatoprost - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
bimatoprost SR - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
DE-117 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
decorin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Glaucoma-GT - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
HPP-851 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
latanoprost - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
latanoprost - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
latanoprost SR - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
latanoprost SR - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
latanoprostene bunod - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
levobetaxolol hydrochloride - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
netarsudil mesylate - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
ONO-9054 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
OPA-6566 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
R-801 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
RG-4929 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
ripasudil - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
RO-5093151 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
SAR-366234 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Small Molecules to Antagonize CXCR3 for Glaucoma - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
SNJ-1656 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
trabodenoson - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
travoprost SR - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Open-Angle Glaucoma - Recent Pipeline Updates 97
Open-Angle Glaucoma - Dormant Projects 112
Open-Angle Glaucoma - Discontinued Products 113
Open-Angle Glaucoma - Product Development Milestones 114
Featured News & Press Releases 114
Mar 03, 2016: Aerie Pharmaceuticals Announces Availability on Its Website of Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting 114
Feb 22, 2016: Aerie Pharmaceuticals Announces Four New Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting Next Week 114
Sep 22, 2015: Bausch + Lomb and Nicox Announce FDA Acceptance of New Drug Application for Novel Glaucoma Candidate VESNEO (latanoprostene bunod) 115
Mar 13, 2012: NicOx, Bausch + Lomb's Glaucoma Candidate BOL-303259-X Meets Primary Endpoint In Phase IIb Study 116
Nov 28, 2011: NicOx Announces Completion Of Patient Recruitment In Glaucoma Study 117
Mar 10, 2010: Qlt Announces Phase II Clinical Trial Results And Development Plans For The Punctal Plug Delivery System 117
Jul 28, 2009: Qlt Announces Interim Data From A Phase II Clinical Trial And A Device Study For A Punctal Plug Drug Delivery System 118
Appendix 120
Methodology 120
Coverage 120
Secondary Research 120
Primary Research 120
Expert Panel Validation 120
Contact Us 120
Disclaimer 121

List of Tables
Number of Products under Development for Open-Angle Glaucoma, H1 2016 11
Number of Products under Development for Open-Angle Glaucoma - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 14
Number of Products under Development by Companies, H1 2016 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2016 16
Comparative Analysis by Late Stage Development, H1 2016 17
Comparative Analysis by Clinical Stage Development, H1 2016 18
Comparative Analysis by Early Stage Development, H1 2016 19
Comparative Analysis by Unknown Stage Development, H1 2016 20
Products under Development by Companies, H1 2016 21
Products under Development by Companies, H1 2016 (Contd..1) 22
Products under Investigation by Universities/Institutes, H1 2016 23
Open-Angle Glaucoma - Pipeline by Aerie Pharmaceuticals, Inc., H1 2016 24
Open-Angle Glaucoma - Pipeline by Allergan Plc, H1 2016 25
Open-Angle Glaucoma - Pipeline by Amakem NV, H1 2016 26
Open-Angle Glaucoma - Pipeline by Asahi Kasei Pharma Corp., H1 2016 27
Open-Angle Glaucoma - Pipeline by Bausch & Lomb Incorporated, H1 2016 28
Open-Angle Glaucoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 29
Open-Angle Glaucoma - Pipeline by Inotek Pharmaceuticals Corporation, H1 2016 30
Open-Angle Glaucoma - Pipeline by Kowa Company, Ltd., H1 2016 31
Open-Angle Glaucoma - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016 32
Open-Angle Glaucoma - Pipeline by Ocular Therapeutix, Inc., H1 2016 33
Open-Angle Glaucoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 34
Open-Angle Glaucoma - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 35
Open-Angle Glaucoma - Pipeline by Oxford BioMedica Plc, H1 2016 36
Open-Angle Glaucoma - Pipeline by Sanofi, H1 2016 37
Open-Angle Glaucoma - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016 38
Open-Angle Glaucoma - Pipeline by Senju Pharmaceutical Co., Ltd., H1 2016 39
Open-Angle Glaucoma - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 40
Open-Angle Glaucoma - Pipeline by Sylentis S.A.U., H1 2016 41
Open-Angle Glaucoma - Pipeline by ViSci Ltd., H1 2016 42
Open-Angle Glaucoma - Pipeline by vTv Therapeutics LLC, H1 2016 43
Assessment by Monotherapy Products, H1 2016 44
Assessment by Combination Products, H1 2016 45
Number of Products by Stage and Target, H1 2016 47
Number of Products by Stage and Mechanism of Action, H1 2016 50
Number of Products by Stage and Route of Administration, H1 2016 52
Number of Products by Stage and Molecule Type, H1 2016 54
Open-Angle Glaucoma Therapeutics - Recent Pipeline Updates, H1 2016 97
Open-Angle Glaucoma - Dormant Projects, H1 2016 112
Open-Angle Glaucoma - Discontinued Products, H1 2016 113

List of Figures
Number of Products under Development for Open-Angle Glaucoma, H1 2016 11
Number of Products under Development for Open-Angle Glaucoma - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 16
Comparative Analysis by Late Stage Development, H1 2016 17
Comparative Analysis by Clinical Stage Development, H1 2016 18
Comparative Analysis by Early Stage Products, H1 2016 19
Assessment by Monotherapy Products, H1 2016 44
Assessment by Combination Products, H1 2016 45
Number of Products by Top 10 Targets, H1 2016 46
Number of Products by Stage and Top 10 Targets, H1 2016 46
Number of Products by Top 10 Mechanism of Actions, H1 2016 49
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 49
Number of Products by Routes of Administration, H1 2016 51
Number of Products by Stage and Routes of Administration, H1 2016 51
Number of Products by Molecule Types, H1 2016 53
Number of Products by Stage and Molecule Types, H1 2016 53

Companies Mentioned

Aerie Pharmaceuticals, Inc.
Allergan Plc
Amakem NV
Asahi Kasei Pharma Corp.
Bausch & Lomb Incorporated
F. Hoffmann-La Roche Ltd.
Inotek Pharmaceuticals Corporation
Kowa Company, Ltd.
Lee's Pharmaceutical Holdings Limited
Ocular Therapeutix, Inc.
Ono Pharmaceutical Co., Ltd.
Otsuka Holdings Co., Ltd.
Oxford BioMedica Plc
Sanofi
Santen Pharmaceutical Co., Ltd.
Senju Pharmaceutical Co., Ltd.
Sun Pharma Advanced Research Company Ltd.
Sylentis S.A.U.
ViSci Ltd.
vTv Therapeutics LLC


LICENSE TYPE